Black Diamond Therapeutics — Q3 2026 Earnings Summary

Black Diamond Therapeutics reported updated Phase 2 results for silevertinib showing an 86% central nervous system objective response rate and a median progression-free survival of 12.2 months in patients with untreated brain metastases. Following a collaborative End-of-Phase 2 meeting with the FDA, the company received support for a pivotal Phase 3 trial design targeting accelerated approval based on CNS response and full approval based on progression-free survival. The company plans to initiate this global Phase 3 registrational trial in the second quarter of 2027 with 300 patients harboring EGFR non-classical mutations. Financially, Black Diamond ended the third quarter of 2026 with $102.0 million in cash and cash equivalents, which is projected to fund operations through the second half of 2028.